Defects in antigen presentation are associated with resistance to T cell-mediated tumor killing35–37, hence, upregulation of MHC class I expression on tumor cells by SHP2 blockade provides a rationale for combining SHP2 inhibition with immunotherapy in cancer patients. This evidence concerns the gene PTPN11 and neoplasm.